Literature DB >> 21268367

[Morphologic and molecular manifestations of hybrid dysgenesis in ontogenesis of Drosophila virilis].

M I Sokolova, E S Zelentsova, N V Rozhkov, M B Evgen'ev.   

Abstract

Disorders of germ track cell development that take place in crossbreeding of certain lines of Drosophila virilis and lead to hybrid dysgenesis (HD) syndrome have been studied. Polar cells and germ line cells were identified with specific antibodies against Vasa protein. It has been shown that abnormalities of formation of primary gonads takes place already at the 11-12 stage of embryo development and the consequences of germ line cell death lead to disorders of gonad development at the following stages of ontogenesis of dysgenic hybrids. The start point of germ line cell death in embryogenesis as well as initiation of transcription of Penelope retroelement, which is supposed to play a significant role in HD syndrome development in D. virilis, were estimated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21268367

Source DB:  PubMed          Journal:  Ontogenez        ISSN: 0475-1450


  3 in total

1.  P elements and the determinants of hybrid dysgenesis have different dynamics of propagation in Drosophila melanogaster populations.

Authors:  Olesia M Ignatenko; Lyudmila P Zakharenko; Natalia V Dorogova; Svetlana A Fedorova
Journal:  Genetica       Date:  2015-11-04       Impact factor: 1.082

2.  Expression of Drosophila virilis retroelements and role of small RNAs in their intrastrain transposition.

Authors:  Nikolay V Rozhkov; Elena S Zelentsova; Natalia G Shostak; Michael B Evgen'ev
Journal:  PLoS One       Date:  2011-07-11       Impact factor: 3.240

3.  Hybrid dysgenesis in Drosophila virilis results in clusters of mitotic recombination and loss-of-heterozygosity but leaves meiotic recombination unaltered.

Authors:  Lucas W Hemmer; Guilherme B Dias; Brittny Smith; Kelley Van Vaerenberghe; Ashley Howard; Casey M Bergman; Justin P Blumenstiel
Journal:  Mob DNA       Date:  2020-02-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.